Maze Therapeutics, Inc. - 10-Q Filing
Maze Therapeutics filed a Form 10-Q for the quarter ended March 31, 2026, disclosing financial results and operational updates including R&D expenses, general and administrative costs, and details of its Hercules Term Loan Facility. The company also outlined subsequent events such as an underwriting agreement related to pre-funded warrants.
Tickers: $MAZE